Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of Type 1 Diabetes Mellitus (T1DM) that has gained popularity due to reported improvements in metabolic control and flexibility. Despite the growing number of CSII users, there is limited research exploring the everyday experiences living with this device. The purpose of my study was to understand the lived experience of adults using CSII therapy to manage T1DM. Accounts of lived experiences from eight individuals were collected through semi-structured interviews and then analysed using Max van Manen’s (1990) hermeneutic approach to phenomenology. Four substantive themes with supporting subthemes were identified including transitioning: not a qu...
Type 1 diabetes (T1DM) is managed by exogenous insulin administration, either by multiple daily inje...
The population of patients who have been diagnosed with diabetes mellitus (Type 1 or Type 2) has bee...
This chapter deals with clinical trials and routine management of persons with type 1 diabetes (PWD1...
Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of T...
Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of T...
© 2017 John Wiley & Sons, Ltd. Rationale, aims, and objectives: Use of continuous subcutaneous insul...
Diabetes affects an estimated 29.1 million Americans, with approximately another 1/3 of Americans no...
Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective method of achievin...
Adolescent athletes with type 1 diabetes (T1DM) face unique challenges when compared to peers with a...
Type 1 diabetes in adulthood permeates every aspect of life. While previous research has been carrie...
Diabulimia is the term given to the intentional restriction of insulin for the purposes of weight lo...
Introduction: Continuous subcutaneous insulin infusion (CSII) treatment is beneficial for obtaining ...
The goal of this study was to determine the effectiveness of insulin delivered via multiple injectio...
BACKGROUND: Insulin pump therapy (IPT) is a technological advancement that has been developed to hel...
Abstract Aims The aim of this study was to compare individuals with type 1 diabetes with continuous ...
Type 1 diabetes (T1DM) is managed by exogenous insulin administration, either by multiple daily inje...
The population of patients who have been diagnosed with diabetes mellitus (Type 1 or Type 2) has bee...
This chapter deals with clinical trials and routine management of persons with type 1 diabetes (PWD1...
Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of T...
Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of T...
© 2017 John Wiley & Sons, Ltd. Rationale, aims, and objectives: Use of continuous subcutaneous insul...
Diabetes affects an estimated 29.1 million Americans, with approximately another 1/3 of Americans no...
Evidence suggests continuous subcutaneous insulin infusion (CSII) is an effective method of achievin...
Adolescent athletes with type 1 diabetes (T1DM) face unique challenges when compared to peers with a...
Type 1 diabetes in adulthood permeates every aspect of life. While previous research has been carrie...
Diabulimia is the term given to the intentional restriction of insulin for the purposes of weight lo...
Introduction: Continuous subcutaneous insulin infusion (CSII) treatment is beneficial for obtaining ...
The goal of this study was to determine the effectiveness of insulin delivered via multiple injectio...
BACKGROUND: Insulin pump therapy (IPT) is a technological advancement that has been developed to hel...
Abstract Aims The aim of this study was to compare individuals with type 1 diabetes with continuous ...
Type 1 diabetes (T1DM) is managed by exogenous insulin administration, either by multiple daily inje...
The population of patients who have been diagnosed with diabetes mellitus (Type 1 or Type 2) has bee...
This chapter deals with clinical trials and routine management of persons with type 1 diabetes (PWD1...